by Adam | Dec 15, 2020 | News
PROVIDENCE, RI, December 15, 2020 /PRNewswire/ — EpiVax, Inc. reports a record-breaking year for the “ISPRI” immunogenicity screening toolkit. More pharmaceutical and biotechnology companies signed new and continuing licenses for access to the toolkit in 2020...
by Adam | Nov 6, 2019 | News
Providence, November 6th 2019 EpiVax announces Publication of Antigen-Specific Tolerance Induction by Tregitope in Nature Scientific Reports EpiVax, Inc (“EpiVax”), a pioneer in immunoinformatics innovation, announces the publication of “Therapeutic administration of...
by Adam | Oct 23, 2019 | News
Announced today, Chugai Pharmaceutical Co., Ltd. (“Chugai”), a member of the Roche Group, will extend the company’s licensed access to the Immunogenicity Screening and Protein Reengineering Interface (ISPRI) toolkit developed by EpiVax, Inc....
by Adam | Dec 29, 2018 | News
EpiVax Re-Pledges Commitment to Improving [Human] Health Everywhere Providence, R.I., December 28th, 2018 EpiVax, Inc. is once more pledging to fulfill its mission to “improve human health everywhere”. The employees of this Providence-based, privately-owned...
